Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
EARLY_PHASE1
20
about 5.5 years
1–85
2 sites in OH
What this study is about
This trial is testing if donor virus-specific cytotoxic T lymphocytes (CTLs) can treat cytomegalovirus (CMV) or adenovirus (AdV) reactivation or infection in people who have had a stem cell transplant or solid organ transplant. White blood cells from donors may be able to kill cancer cells in patients with CMV or AdV that has come back after a stem cell or solid organ transplant.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
- 2.Receive Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence of adverse events defined by the National Cancer Institute Common Terminology Criteria for Adverse Events 4.0
Secondary: Antiviral activity defined as response to viral load, Number of participants with treatment-related adverse events as assessed by CTCAE v4.0., Overall survival